688062 迈威生物
已收盘 03-06 15:00:01
资讯
新帖
简况
3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 03-03
3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股
新股消息 | 迈威生物(688062.SH)港股IPO招股书失效
智通财经 · 03-02
新股消息 | 迈威生物(688062.SH)港股IPO招股书失效
股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元
证券之星 · 03-02
股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元
每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄
证券之星 · 03-01
每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄
迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%
证券之星 · 02-27
迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%
证券之星 · 02-24
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%
每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案
中金财经 · 02-15
每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
证券之星 · 02-02
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
证券之星 · 01-28
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
迈威生物：公司负责大中华区和东南亚区域的开发及商业化
证券日报 · 01-28
迈威生物：公司负责大中华区和东南亚区域的开发及商业化
股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元
证券之星 · 01-26
股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元
每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元
证券之星 · 01-25
每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元
迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元
证券之星 · 01-23
迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元
迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药
美股速递 · 01-22
迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药
迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%
证券之星 · 01-21
迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%
1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股
证券之星 · 01-07
1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股
迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药
美股速递 · 2025-12-30
迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
证券之星 · 2025-12-28
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
证券之星 · 2025-12-25
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
暂无数据
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":34.19,"timestamp":1772780401000,"preClose":32.27,"halted":0,"volume":7455530,"delay":0,"changeRate":0.0595,"floatShares":204000000,"shares":400000000,"eps":-2.3711,"marketStatus":"已收盘","change":1.92,"latestTime":"03-06 15:00:01","open":32.3,"high":34.36,"low":32.22,"amount":251000000,"amplitude":0.0663,"askPrice":34.19,"askSize":20,"bidPrice":34.18,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.3711,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773019800000},"marketStatusCode":5,"adr":0,"adjPreClose":32.27,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":35.5,"lowLimit":29.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"isCdr":false,"pbRate":17.95,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.13278,"marketValue":13662000000,"turnoverRate":0.0365,"status":0,"afterMarket":{"amount":0,"volume":0,"close":34.19,"buyVolume":0,"sellVolume":0,"time":1772782437558,"indexStatus":"已收盘 03-06 15:30:00","preClose":32.27},"floatMarketCap":6981000000},"requestUrl":"/m/hq/s/688062/tweets","defaultTab":"tweets","newsList":[{"id":"2616312410","title":"3月3日迈威生物跌5.58%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312410?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:33","pubTimestamp":1772526805,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日迈威生物跌5.58%创60日新低，收盘报31.65元，换手率3.97%，成交量8.11万手，成交额2.62亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.698，较上一交易日下跌2.66%，近一年上涨14.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300028938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2616013478","title":"新股消息 | 迈威生物(688062.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2616013478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616013478?lang=zh_cn&edition=full","pubTime":"2026-03-02 11:43","pubTimestamp":1772423014,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威(上海)生物科技股份有限公司(迈威生物)(688062.SH)于2025年8月29日所递交的港股招股书满6个月，于近日失效。据招股书，迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。多年来，公司建立了具有竞争力的、多层次的管线产品组合，包括10个以上的药物资产且覆盖不同品种，专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VT","688062","BK4585","VXUS","BK0239"],"gpt_icon":0},{"id":"2616875172","title":"股市必读：迈威生物发布2025年度业绩快报，亏损9.702亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616875172","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616875172?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:14","pubTimestamp":1772388853,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，上涨0.37%，换手率1.72%，成交量3.51万手，成交额1.23亿元。来自业绩披露要点：迈威生物预计2025年归属净利润亏损9.702亿元，同比收窄7.06%。公司公告汇总迈威生物2025年度业绩快报公告迈威生物发布2025年度业绩快报，营业总收入66,251.56万元，同比增长231.62%。归属于母公司所有者权益同比下降77.78%，主要因研发投入高、商业化拓展致成本费用上升。加权平均净资产收益率下降48.77个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2616431078","title":"每周股票复盘：迈威生物（688062）2025年净亏9.7亿同比收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2616431078","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616431078?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，较上周的36.42元下跌4.09%。本周，迈威生物2月24日盘中最高价报36.7元。迈威生物当前最新总市值139.58亿元，在化学制药板块市值排名39/150，在两市A股市值排名1566/5189。本周关注点来自业绩披露要点：迈威生物2025年归属净利润亏损9.702亿元，同比收窄7.06%。公司公告汇总迈威生物发布2025年度业绩快报，营业总收入66,251.56万元，同比增长231.62%，主要由于与齐鲁制药、DISC MEDICINE, INC.的授权许可合同确认收入较大，以及药品销售收入增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2614524228","title":"迈威生物（688062）披露2025年度业绩快报公告，2月27日股价上涨0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614524228","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614524228?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:50","pubTimestamp":1772203823,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迈威生物报收于34.93元，较前一交易日上涨0.37%，最新总市值为139.58亿元。该股当日开盘34.78元，最高35.25元，最低34.51元，成交额达1.23亿元，换手率为1.72%。公告显示，公司2025年营业总收入为66,251.56万元，同比增长231.62%。营业利润为-95,615.95万元，归属于母公司所有者的净利润为-97,017.55万元。归属于母公司所有者权益同比下降77.78%，主要因研发投入高、商业化拓展致成本费用上升。加权平均净资产收益率下降48.77个百分点。上述数据为初步核算结果，未经审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2613079166","title":"迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，2月24日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613079166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613079166?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925574,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，迈威生物报收于35.23元，较前一交易日下跌3.27%，最新总市值为140.78亿元。该股当日开盘36.7元，最高36.7元，最低35.0元，成交额达2.02亿元，换手率为2.78%。公告显示，公司于2026年2月13日召开2026年第一次临时股东会，审议通过《关于公司调整部分募投项目内部投资结构的议案》。出席会议的股东共129人，代表有表决权股份总数205,575,336股，占公司总表决权数的51.4452%。该议案对中小投资者单独计票，表决程序符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2611614497","title":"每周股票复盘：迈威生物（688062）股东会通过募投项目调整议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2611614497","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611614497?lang=zh_cn&edition=full","pubTime":"2026-02-15 08:05","pubTimestamp":1771113913,"startTime":"0","endTime":"0","summary":"本周，迈威生物2月10日盘中最高价报37.89元。迈威生物当前最新总市值145.53亿元，在化学制药板块市值排名36/150，在两市A股市值排名1456/5189。出席会议的股东共129人，代表有表决权股份总数205,575,336股，占公司总表决权数的51.4452%。北京植德(上海)律师事务所对本次会议出具法律意见，确认会议召集、召开程序及表决结果合法有效。会议审议通过《关于公司调整部分募投项目内部投资结构的议案》，无关联股东需回避表决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260215/32019328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2608851807","title":"2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851807?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:40","pubTimestamp":1770021648,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日迈威生物创60日新低，收盘报34.78元，当日跌3.42%，换手率3.14%，成交量6.41万手，成交额2.27亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.96，较上一交易日下跌0.13%，近一年上涨33.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2606717868","title":"迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717868?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:14","pubTimestamp":1769609661,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，迈威生物报收于37.75元，较前一交易日下跌1.95%，最新总市值为150.85亿元。近日，迈威（上海）生物科技股份有限公司发布《2026年第一次临时股东会会议资料》公告，拟对2022年首次公开发行股份募投项目中的“抗体药物研发项目”内部投资结构进行调整，减少9MW0311、9MW0321、8MW0511、9MW1111、9MW1411、6MW3211项目的募集资金投入合计9,083.18万元，并将该部分资金用于增加9MW2821项目的投入。本次调整不涉及募投项目计划投入募集资金总额的变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2606167927","title":"迈威生物：公司负责大中华区和东南亚区域的开发及商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2606167927","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606167927?lang=zh_cn&edition=full","pubTime":"2026-01-28 20:11","pubTimestamp":1769602260,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月28日，迈威生物在互动平台回答投资者提问时表示，公司研发的重组抗TMPRSS6单克隆抗体创新药9MW3011为全球唯一一款用于真性红细胞增多症 治疗的靶向TMPRSS6单抗，该管线公司已经实现对外授权合作，公司负责大中华区和东南亚区域的开发及商业化，其他区域由合作伙伴DISCMEDICINE，INC.全面推进并先后获得美国FDA授予“快速通道认定”和“孤儿药资格认定”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-28/doc-inhiwnws4788037.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-28/doc-inhiwnws4788037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2606526595","title":"股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606526595","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606526595?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:16","pubTimestamp":1769368573,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，迈威生物报收于40.3元，上涨2.23%，换手率3.4%，成交量6.94万手，成交额2.81亿元。业绩披露要点业绩预告迈威生物发布业绩预告，预计2025年全年归属净利润亏损9亿元至9.95亿元；扣非后净利润亏损9.05亿元至9.99亿元。公司公告汇总迈威生物2025年年度业绩预告迈威生物预计2025年度归属于母公司所有者的净利润为-90,000.00万元到-99,450.00万元，扣除非经常性损益后净利润为-90,500.00万元到-99,950.00万元，较上年同期亏损收窄。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"2606232739","title":"每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232739","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232739?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:13","pubTimestamp":1769281990,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，迈威生物报收于40.3元，较上周的43.24元下跌6.8%。本周，迈威生物1月19日盘中最高价报43.55元。本周关注点业绩披露要点：迈威生物预计2025年归属净利润亏损9亿元至9.95亿元。公司公告汇总：迈威生物拟继续使用不超过8亿元闲置募集资金进行现金管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2605784354","title":"迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605784354","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605784354?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:53","pubTimestamp":1769158404,"startTime":"0","endTime":"0","summary":"证券之星消息，迈威生物发布业绩预告，预计2025年全年归属净利润亏损9亿元至9.95亿元。迈威生物2025年三季报显示，前三季度公司主营收入5.66亿元，同比上升301.03%；归母净利润-5.98亿元，同比上升13.89%；扣非净利润-6.22亿元，同比上升12.91%；其中2025年第三季度，公司单季度主营收入4.65亿元，同比上升1717.41%；单季度归母净利润-4634.11万元，同比上升81.4%；单季度扣非净利润-4881.64万元，同比上升80.77%；负债率79.11%，投资收益-577.49万元，财务费用5837.5万元，毛利率93.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300027276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"1126502808","title":"迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1126502808","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126502808?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:07","pubTimestamp":1769090863,"startTime":"0","endTime":"0","summary":"迈威生物（Mabwell）宣布，其研发的新型靶向Cdh17的抗体偶联药物（ADC）7Mw4911已在美国完成首例患者临床试验给药。这一里程碑标志着该创新疗法正式进入临床研究阶段，为后续开发奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2605835104","title":"迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605835104","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605835104?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:24","pubTimestamp":1769005464,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，迈威生物报收于40.01元，较前一交易日下跌0.42%，最新总市值为159.88亿元。近日，迈威生物发布公告称，公司于2026年1月21日召开董事会，审议通过继续使用不超过8亿元的暂时闲置募集资金进行现金管理，投资安全性高、流动性好、有保本约定的产品，使用期限为自董事会审议通过之日起12个月内，资金可循环滚动使用。保荐机构对本次现金管理事项无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2601141827","title":"1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601141827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601141827?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:33","pubTimestamp":1767771216,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日迈威生物涨9.55%，收盘报45.2元，换手率7.52%，成交量15.35万手，成交额6.78亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家；过去90天内机构目标均价为55.42。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为新华基金的新华优选分红混合A。该公募基金现任基金经理为赵强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700017945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"1159975946","title":"迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1159975946","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159975946?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:03","pubTimestamp":1767103387,"startTime":"0","endTime":"0","summary":"迈威生物宣布，其针对病理性瘢痕开发的抗IL-11抗体药物二期临床试验已顺利完成首例患者给药。该试验旨在评估该创新疗法在改善瘢痕形成方面的安全性与有效性，标志着公司在自身免疫及纤维化疾病领域取得重要进展。此次临床推进为后续研究奠定了关键基础，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594244551","title":"每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244551","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244551?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:29","pubTimestamp":1766860149,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，迈威生物报收于39.94元，较上周的39.61元上涨0.83%。本周关注点公司公告汇总：9MW1911注射液临床试验申请获FDA许可，拟在美国开展针对中重度COPD患者的IIa期临床研究。该药品为自主开发的抗ST2单克隆抗体，已在境内完成IIa期临床试验，安全性良好，药代动力学和初步疗效数据支持进一步开发。目前IIb期临床试验正在积极入组，计划2026年底启动III期研究。表决程序合法，表决结果有效。董事会成员仍为9名，符合相关法规要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594237416","title":"迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237416","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237416?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:33","pubTimestamp":1766673197,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，迈威生物报收于40.2元，较前一交易日上涨0.9%，最新总市值为160.64亿元。近日，迈威（上海）生物科技股份有限公司召开2025年第三次临时股东大会，审议通过了《关于取消监事会、修订〈公司章程〉及相关议事规则的议案》及《关于修订部分公司治理制度的议案》。其中，取消监事会及修订公司章程为特别决议议案，已获出席股东所持表决权2/3以上通过；其余治理制度修订为普通决议议案，获1/2以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","03692","688062","LU1997244956.HKD","LU0405327148.USD","01530","600276","LU2148510915.USD","LU1328615791.USD","02142","LU2580892862.HKD","01167","LU2097828805.USD","LU0405327494.USD","02096","BK1593","LU1781817850.SGD","000661","002755","LU0502904849.HKD","LU1146622755.USD","LU2097828474.EUR","01801","688331","688336","BK0196","BK1589","LU1997245177.USD","BK1161","BK0060","BK1574","BK0057","BK0188","BK0239","BK0012","LU2488822045.USD","688428","02509","603087","BK0028","LU1969619763.USD","LU2495084118.USD","LU2097828557.USD","BK0183","LU1997245094.SGD","06978","LU2097828631.EUR","09995","LU2097828714.EUR","LU1064130708.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772801107368,"stockEarnings":[{"period":"1week","weight":-0.0727},{"period":"1month","weight":-0.0918},{"period":"3month","weight":-0.2504},{"period":"6month","weight":-0.4457},{"period":"1year","weight":0.7396},{"period":"ytd","weight":-0.1612}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19583人(较上一季度增加9.15%)","perCapita":"10425股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"39960万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}